8-K: Atara Biotherapeutics Reports Positive Q3 Results and Advances Pipeline

Atara Biotherapeutics announced its third quarter 2024 financial results, highlighting progress in its pipeline and a strengthened cash position.

Summary

• Atara Biotherapeutics reported its third quarter 2024 financial results, showing a significant increase in revenue and a reduction in operating expenses.
• The company's cash position improved to $67.2 million as of September 30, 2024, up from $35.3 million at the end of the previous quarter, due to milestone payments, inventory sales, and a direct offering.
• Net cash used in operating activities decreased substantially to $4.0 million in Q3 2024, compared to $51.3 million in the same period in 2023.
• Total revenues for Q3 2024 were $40.2 million, a significant increase from $2.1 million in Q3 2023, primarily due to the expanded partnership with Pierre Fabre.
• The company reported a net loss of $21.9 million, or $2.93 per share, for the third quarter 2024, compared to a net loss of $69.8 million, or $16.40 per share, for the same period in 2023.
• Atara expects full year 2024 operating expenses to decrease by approximately 35% from 2023.
• The company anticipates its cash runway will extend into 2027, supported by milestone payments, inventory sales, and operating efficiencies.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with significant improvements in financial results, progress in clinical trials, and a clear path forward. The company's cash runway is extended, and key milestones are on track, indicating a strong position for future growth. The only negative is the ongoing dispute with MSK.

Positives

• The company's cash position has significantly improved, providing financial stability.
• Revenue has increased dramatically due to the expanded partnership with Pierre Fabre.
• Operating expenses have been reduced, leading to a lower net loss.
• The company has made significant progress in its clinical trials, with the first patient dosed in the ATA3219 NHL trial.
• The tab-cel BLA is on track with a PDUFA target action date of January 15, 2025.
• Atara is expanding its pipeline with new studies for ATA3219 in lupus nephritis and extrarenal systemic lupus erythematosus.
• The company has secured a $60 million milestone payment from Pierre Fabre contingent upon FDA approval of the tab-cel BLA.

Negatives

• Atara paid a $6.0 million sub-licensing fee to Memorial Sloan Kettering Cancer Center under protest.
• The company is still operating at a loss, although the loss has been significantly reduced.
• There is ongoing disagreement with Memorial Sloan Kettering Cancer Center regarding licensing fees.

Risks

• The company is involved in a dispute with Memorial Sloan Kettering Cancer Center over licensing fees, which could lead to further costs.
• The success of the clinical trials for ATA3219 and ATA3431 is not guaranteed.
• The company's financial projections are based on several assumptions, including the approval of the tab-cel BLA and the receipt of milestone payments.
• The company is subject to risks and uncertainties associated with the pharmaceutical product development process, including clinical trial success and regulatory approvals.
• The COVID-19 pandemic and the wars in Ukraine and the Middle East may impact the company's business, research, and clinical development plans.

Future Outlook

Atara anticipates its cash runway will extend into 2027, supported by milestone payments, inventory sales, and operating efficiencies. The company expects the first quarter of 2025 to be transformational with the potential FDA approval of tab-cel and the transition of that business to Pierre Fabre, allowing Atara to focus on its allogeneic CAR-T pipeline.

Management Comments

• With the first patient now enrolled in our Phase 1 NHL trial of ATA3219, we have taken an important step in applying our proven Epstein-Barr virus platform to the significant opportunity in allogeneic CAR T, said Cokey Nguyen, Ph.D., President and Chief Executive Officer of Atara.
• The first quarter of 2025 is positioned to be transformational for the company, with the potential for FDA approval of tab-cel and transition of this business to our partner Pierre Fabre, repositioning Atara as a fully focused allogeneic CAR-T company with multiple near-term data milestones for our lead program in oncology and autoimmune indications.

Industry Context

This announcement reflects a broader trend in the biotechnology industry towards the development of allogeneic cell therapies, particularly in the areas of oncology and autoimmune diseases. Atara's focus on its EBV T-cell platform and its partnerships with companies like Pierre Fabre are indicative of the industry's move towards more efficient and scalable therapeutic solutions.

Comparison to Industry Standards

• Atara's Q3 2024 revenue of $40.2 million is a significant increase compared to the $2.1 million in Q3 2023, primarily due to the expanded partnership with Pierre Fabre. This is a positive sign compared to other biotech companies that may struggle with revenue generation in early stages.
• The reduction in net loss from $69.8 million in Q3 2023 to $21.9 million in Q3 2024 indicates improved financial management and operational efficiency, which is a key metric for investors in the biotech sector.
• The cash runway extending into 2027 is a positive indicator of financial stability, which is crucial for biotech companies that require significant capital for research and development. This is better than many companies that have a cash runway of only 12-24 months.
• The progress of the tab-cel BLA with a PDUFA target action date of January 15, 2025, is a critical milestone. The success of this BLA will be a key benchmark for Atara compared to other companies in the cell therapy space.
• The initiation of Phase 1 studies for ATA3219 in lupus nephritis and extrarenal systemic lupus erythematosus by the end of the year is a positive step in expanding the company's pipeline. This is comparable to other companies that are also exploring CAR-T therapies for autoimmune diseases.
• The company's focus on allogeneic CAR-T therapies is in line with the industry trend towards off-the-shelf therapies, which are more scalable and accessible than autologous therapies. This is a key differentiator for Atara compared to companies that are still focused on autologous approaches.

Management Changes

Legal Proceedings

• Atara is entering into evaluative non-binding mediation to potentially resolve a disagreement with Memorial Sloan Kettering Cancer Center regarding a $6.0 million sub-licensing fee.

Stakeholder Impact

• Shareholders will likely view the improved financial results and extended cash runway positively.
• Employees may benefit from the company's improved financial stability and continued progress in its pipeline.
• Patients may benefit from the development of new therapies for cancer and autoimmune diseases.
• The partnership with Pierre Fabre is expected to benefit both companies through the commercialization of tab-cel.

Next Steps

• The company will continue to advance the tab-cel BLA towards the PDUFA target action date of January 15, 2025.
• Atara will initiate Phase 1 studies of ATA3219 for lupus nephritis and extrarenal systemic lupus erythematosus by the end of the year.
• The company will continue to progress the Phase 1 clinical study of ATA3219 for NHL, with initial clinical data expected in Q1 2025.
• Atara will progress towards an IND submission for ATA3431 in Q4 2025.
• The company will continue to work towards the transition of substantially all activities relating to tab-cel to Pierre Fabre, potentially as early as Q1 2025.

Key Dates

Keywords

Atara Biotherapeutics, T-cell immunotherapy, tab-cel, ATA3219, ATA3431, allogeneic CAR T, Epstein-Barr virus, Non-Hodgkins Lymphoma, Lupus Nephritis, FDA, PDUFA, Pierre Fabre, clinical trials, biologics license application, financial results